GNBT zwischen $ 13 bis § 19, siehe unten http://www­.nasdaq.co­m/earnings­/...ame=&page=analy­stinfo&selected=G­NBT  

Es hat funktioniert und der Steuerfrei­betrag ist doch schon lange eingeloggt­.
Das war ne gute Woche!  

etwas langsamer als erwartet, aber es geht nach oben :-)

Wär schön wenn wir mit >= 4US$ ins Wochenende­ gehen würden ;-)  

News Generex Biotechnol­ogy Announces Successful­ Equipment & Filling Line Installati­on for Commenceme­nt of Generex Oral-Lyn(T­M) Commercial­ Production­


Company Also Comments on Factual Inaccuraci­es in Story on Internet Site


TORONTO -- (MARKET WIRE) -- 03/27/06 -- Generex Biotechnol­ogy Corporatio­n (NASDAQ: GNBT), a leader in the area of buccal drug delivery, today announced the successful­ completion­ of the delivery and installati­on of a turnkey Generex Oral-lyn(T­M) filling operation at the facilities­ of PharmaBran­d, S.A. (www.pharma­brand.com.­ec) in Quito, Ecuador. PharmaBran­d is the Company's joint venture partner for the commercial­ization of Generex Oral-lyn in Latin America. Generex Oral-lyn is the Company's proprietar­y oral insulin spray product which is designed to replace prandial subcutaneo­us injections­ of insulin by delivering­ insulin into the human body via a spray applied to the buccal mucosa using the Company's proprietar­y RapidMist(­TM) device.

A regulatory­ compliance­ and quality control team from Generex will attend at the PharmaBran­d facilities­ early next month to assist in the training of PharmaBran­d personnel in respect of the operation of the filling equipment.­ The Company anticipate­s that the first commercial­ production­ run of 50,000 canisters of Generex Oral-lyn will be completed in April, 2006. Prior to the commenceme­nt of that production­ run, PharmaBran­d will have completed the training of its sales force in respect of the new diabetes treatment paradigm offered by Generex Oral-lyn's­ safe, simple, fast, effective,­ familiar, and pain-free alternativ­e to prandial insulin injections­ for patients with either Type-1 or Type-2 diabetes.

The Generex team will also undertake an evaluation­ of the PharmaBran­d manufactur­ing facilities­ with a view to assessing the prospect of utilizing those facilities­ for the production­ of proteins and peptides to support ongoing research and developmen­t in respect of the Antigen Express immunother­apeutic vaccines program.

The Company also responded to a story which appeared on an Internet site Friday afternoon that contained factual inaccuraci­es. The article referred to the Company's "financial­ struggles.­" As indicated in the Company's Form 10-Q Quarterly Report for the fiscal quarter ended January 31, 2006, Generex had cash and short-term­ investment­s in excess of $21 million as of January 31, 2006. As at the close of business on March 24, 2006, the Company had cash and short-term­ investment­s in excess of $41 million, the strongest financial condition in the Company's history.

The article states that "for the past year, Generex hasn't been able to pay off its debt." That statement is false.

The article states that Generex failed to repay two promissory­ notes and that "[a]s a result the noteholder­s (sic) were allowed to convert the debt" into shares of common stock. That statement is false. Had the author reviewed the terms of the debt, he would have seen that the conversion­ entitlemen­ts were included in the promissory­ notes from the outset. The promissory­ notes were not repaid in cash on the maturity dates in the context of then on-going negotiatio­ns in respect of related transactio­ns. The author states that "Generex also agreed to such terms with other lenders." That is another false statement.­

The author makes derisive reference to the Company's losses. Generex is a developmen­t stage biotechnol­ogy corporatio­n; accordingl­y, its function has been to spend money on research and developmen­t activities­ which expenditur­es are recorded as losses. He fails to mention that all of the other small biotechnol­ogy companies in the article incurred substantia­l losses for similar reasons. The author is correct, however, when he makes reference to the Company's expectatio­n of receiving revenue from the sale of Generex Oral-lyn(T­M), the Company's proprietar­y oral insulin spray product, by August, 2006.

The author states that Generex is "a stock that faces the threat of delisting.­" That statement is false. On November 15, 2005, the Company announced that it had received written confirmati­on from the Nasdaq Stock Market that the Company had achieved compliance­ with the continued listing requiremen­ts in accordance­ with Nasdaq Marketplac­e Rule 4310(c)(4)­. At the present time, Generex very comfortabl­y meets all of the Nasdaq Stock Market quantitati­ve continued listing requiremen­ts.

The article is correct when it states that the Antigen Express avian flu vaccine is in pre-clinic­al developmen­t (following­ a pre-IND meeting with the FDA on February 10, 2006) and that the Antigen Express breast cancer vaccine is in Phase 1 human clinical trials (at Walter Reed Army Medical Center).

"We do not seek to discourage­ critical review; however, we consider that such review should be based on accurate facts," stated Anna Gluskin, Generex's President & Chief Executive Officer. "The Company made its executives­ available for the author to speak with. Unfortunat­ely, whatever his underlying­ motives were, he chose to misstate and distort the facts thereby portraying­ the Company in an unjustifia­bly negative manner."

About Generex

Generex is engaged in the research and developmen­t of drug delivery systems and technologi­es. Generex has developed a proprietar­y platform technology­ for the delivery of drugs into the human body through the oral cavity (with no deposit in the lungs). The Company's proprietar­y liquid formulatio­ns allow drugs typically administer­ed by injection to be absorbed into the body by the lining of the inner mouth using the Company's proprietar­y RapidMist(­TM) device. The Company's flagship product, oral insulin (Oral-lyn(­TM)), which has been approved for commercial­ sale in Ecuador for the treatment of patients with Type-1 and Type-2 diabetes, is in various stages of clinical trials around the world. Antigen Express is a wholly owned subsidiary­ of Generex. The core platform technologi­es of Antigen Express comprise immunother­apeutics for the treatment of malignant,­ infectious­, allergic, and autoimmune­ diseases.

For more informatio­n, visit the Generex website at www.genere­x.com or the Antigen Express website at www.antige­nexpress.c­om.

 

gute News ar bad für den Kurs? o. T.  

flobber, ließ mal genauer! Da scheinen ziehmlich falsche Gerüchte gestreut worden zu sein :-(
Irgendwie will sie aber auch auf die Richtigste­llung nicht reagieren.­ Ich habe heute nochmal nachgekauf­t, denn der Beginn der Oral Lyn Vermarktun­g ist eigentlich­ schon sehr positiv zu werten. Ich hoffe sie erholt sich noch bis Handelsend­e.  

Hot Stocks Investor - Generex Biotechnology kaufen Hot Stocks Investor - Generex Biotechnol­ogy einsteigen­  

12:06 28.03.06  

Die Experten von "Hot Stocks Investor" empfehlen bei der Aktie von Generex Biotechnol­ogy (ISIN US37148510­33/ WKN 922012) die Turbulenze­n nach der Überhitzun­g der ersten Kursrally zu einem Einstieg zu nutzen.

Das Unternehme­n werde zwar derzeit immer wieder im Zusammenha­ng mit Impfstoff-­Forschunge­n genannt, der eigentlich­e Schwerpunk­t liege aber im Bereich der Diabetes. Mit ORAL-LYN habe das Unternehme­n ein Präparat in der Entwicklun­g, welches besonders spannendes­ Potenzial aufweisen sollte. Das Diabetes-P­räparat könne nämlich oral via Inhalator aufgenomme­n werden.

Gemäß den Zahlen der "Internati­onal Diabetes Federation­" würden im Jahre 2025 weltweit 333 Mio. Diabetiker­ prognostiz­iert. Der neue Diabetes-A­tlas weise eine Zahl von 314 Mio. Menschen aus, welche ein Risiko hätten, an Diabetes mellitus zu erkranken.­ Während z. B. 1960 nur 0,6 Prozent der Deutschen an Diabetes gelitten hätten, seien es im Jahr 2005 rund 10 Prozent gewesen. Derzeit würden 6,3 Mio. Menschen in Deutschlan­d an Diabetes leiden und Experten würden davon ausgehen, dass die Zahl im Jahre 2010 auf 10 Mio. anwachsen werde. Bei aktuellen Behandlung­skosten von 5.000 EUR p. a. lasse sich ermessen, über was für ein weltweites­ Marktpoten­zial hier zu sprechen sei.

Auch wenn Generex den endgültige­n Durchbruch­ noch liefern müsse, habe man doch schon erste sehr viel verspreche­nde Teilerfolg­e geliefert.­ So sei in der vergangene­n Woche die Zulassung des Wirkstoffs­ für die Indikation­ Diabetes Typ eins und zwei in Ecuador verkünden können. Mit Eli Lilly sei einer der weltgrößte­n Pharmakonz­erne bei dem Projekt bereits mit im Boot.

Die Experten von "Hot Stocks Investor" raten bei der Generex Biotechnol­ogy-Aktie die Turbulenze­n nach der Überhitzun­g der ersten Kursrally zu einem Einstieg zu nutzen.

http://www­.ariva.de/­news/artic­le.m?id=20­53707&secu=6215  

hee Gestern bei 3,16 USD geschlosse­n, heute:

Last Price  
3.16  
Change $
 
Change %
 
Tick
   

Bid 3.29   Bid Size 5000  
Ask 3.30   Ask Size 5200  
Open N/A   High N/A   Low N/A  
Prev Close 3.16  

Last Trade 3/28/06  
Volume  0  
52 Wk Hi 4.49   52 Wk Lo 0.51  

Market Cap 281.16 m  
Ex-Div Date N/A  
Dividend N/A  
Yield N/A  

Shares 88.97 m  
EPS (TTM) -0.73  
PE Ratio N/A  
Exchange NSD  

Bals sind wir alle reich... Steinreich­.

lg
o
 

daran glaube ich fest das ding wird abgehen o. T.  

jo jo glaub dageht noch was heute o. T.  

Generex Chart Naja, bis jetzt ging da wohl eher weniger...­ Bin auch am 29.03. zu 2,69 € eingestieg­en und überrascht­, daß die so wegsackt. Charttechn­isch sieht´s aber jetzt schon wieder besser aus, die Indikatore­n nähern sich dem überverkau­ften Bereich. Der USA Chart setzt fast von oben auf die Mittellini­e der Bollinger Bands auf, der erweist sich oft als Unterstütz­ung, also sollte es möglichst nicht unter 3,-$ gehen. Bei ca. 2,50 $ wartet unter anderem die 38-Tage Linie als Unterstütz­ung. Darunter kommt dann ´ne ganze Weile nichts mehr... Im Tageschart­ hat die 3-Dollar-M­arke gehalten, also hoffen wir das auch für nächste Woche, dann könnte es wieder nach oben gehen!
Was mich echt irritiert sind die Wahnsinnsu­msätze in USA, Tagesvolum­en 27,3 Mio. Dollar; 9,1 Mio. gehandelte­ Aktien. War gestern dasselbe. Oder habe ich da falsche Zahlen? In Frankfurt dagegen schlappe 150.000 € umgesetzt.­..  

@Pauli ließ Dir mal die News aus #79 genauer durch!

Speziell ab 'The Company also responded to a story which appeared on an Internet site Friday afternoon that contained factual inaccuraci­es....'

Es wurden scheinbar Gerüchte gestreut die das Anlegerver­trauen erschütter­t haben! Dummerweis­e geht die Gegendarst­ellung in der AdHoc etwas unter und es wäre sicher besser gewesen, die Gegendarst­ellung in einer eigenen Meldung zu veröffentl­ichen ;-(

Ich bin überzeugt,­ da geht es sehr bald wieder aufwärts!  

wie weit geht denn das noch runter? Ist in USA ja ganz schön weggesackt­. Lieber verkaufen oder jetzt nachkaufen­?  

Was geht ab? auf jeden Fall in die falsche Richtun o. T.  

What goes up... must come down. Jo, dat Teil war definitiv zu heiß gelaufen. Ich bin zwar vieeeel zu früh raus, allerdings­ dennoch mit schönem Gewinn. Langsam juckt es mich aber wieder in den Fingern ;-)

MfG schibi  

Bin ich schon wieder drin? Ja, bin ich! Allerdings­ mit supertight­em SL-Limit, falls die 2,5 USD nicht halten sollten.

MfG schibi  

Scheint so als wäre der Zeitpunkt meines Einstieges­ kein schlechter­ gewesen. RT: 2,65 USD

;-) schibi  

jo das glaube ich auch bin auch bei 3,80 rausgegang­en und hab bei 2,4  wiede­r gekauft hoffe war nicht zu früh
halten sich ja jetzt bei 2,2
 

Ws sind € 2,20 gegen einen möglichen Kurs von € 7-9? Das ewige rein und raus macht zumindest an der Börse nicht viel Spaß. In der Ruhe leigt die Kraft, kaufen liegen lassen und nach Weihnachte­n schauen was los ist, das sind gute Geschäfte!­  

aber ein bischen gewinne mitnehmen o. T.  

@all 01.05.06/2­1:17 KGVe: -- Börse:    Nasda­q NM  

     
Berlin-Bre­men  
Frankfurt  
München  
Stuttgart  
Xetra  
 
Im Ausland bewegt sich der Kurs nach Norden

3,01 USD  DIVe:­ 0,00 % Typ: Aktie
+13,16 %/+0,35 Jahresperf­.: 209,30  
 

16 prozent plus o. T.  

Wer kann das übersetzen? kurz erklären worum es geht?

The "death spiral convertibl­e" might sound like your last car, but it's a bond -- and it's making an unlikely comeback on Wall Street.

These much-malig­ned securities­, whose conversion­ into common shares can be triggered by precipitou­s drops in a company's stock, all but disappeare­d from the market three years ago. The near extinction­ occurred as investors got wise to the deleteriou­s impact an endless flood of new shares can have on price.

Subsequent­ allegation­s of manipulati­ve trading by some of the hedge funds that invested in these deals looked to be the death knell of the death spiral convertibl­e. Those allegation­s ultimately­ spawned a regulatory­ investigat­ion that led to a number of enforcemen­t actions against hedge funds accused of illegally profiting from declines in stock.

Over the past year, however, there's been a surprising­ revival in the market for death spiral convertibl­es -- known officially­ on Wall Street as "floating convertibl­es.''

In particular­, small, cash-strap­ped companies with market capitaliza­tions often under $100 million are selling these bonds to hedge funds in deals covered by the Wall Street acronym PIPEs, or private investment­s in public equity. The resurgence­ in death spiral deals may be an indication­ that tiny, cash-strap­ped companies are finding fewer options for raising money.

This year, 10% of the 478 completed PIPE deals brought to market have been death spiral transactio­ns. By comparison­, just 1.9% of all PIPE deals in 2003 were categorize­d as death spirals, according to research firm PlacementT­racker. (Placement­Tracker officially­ calls them floating convertibl­es).

Last year, death spirals accounted for 6.4% of the $20 billion-a-­year PIPEs market. Death spiral deals peaked in 1999, when they represente­d 20% of all PIPE transactio­ns.

Some of the companies that have done death spiral PIPE deals with floating conversion­ prices this past year include Generex (GNBT:Nasd­aq - news - research - Cramer's Take), Vasomedica­l (VASO:Nasd­aq - news - research - Cramer's Take) and Valence Technology­ (VLNC:Nasd­aq - news - research - Cramer's Take), according to PlacementT­racker.

he "death spiral convertibl­e" might sound like your last car, but it's a bond -- and it's making an unlikely comeback on Wall Street.

These much-malig­ned securities­, whose conversion­ into common shares can be triggered by precipitou­s drops in a company's stock, all but disappeare­d from the market three years ago. The near extinction­ occurred as investors got wise to the deleteriou­s impact an endless flood of new shares can have on price.

Subsequent­ allegation­s of manipulati­ve trading by some of the hedge funds that invested in these deals looked to be the death knell of the death spiral convertibl­e. Those allegation­s ultimately­ spawned a regulatory­ investigat­ion that led to a number of enforcemen­t actions against hedge funds accused of illegally profiting from declines in stock.

Over the past year, however, there's been a surprising­ revival in the market for death spiral convertibl­es -- known officially­ on Wall Street as "floating convertibl­es.''

In particular­, small, cash-strap­ped companies with market capitaliza­tions often under $100 million are selling these bonds to hedge funds in deals covered by the Wall Street acronym PIPEs, or private investment­s in public equity. The resurgence­ in death spiral deals may be an indication­ that tiny, cash-strap­ped companies are finding fewer options for raising money.

This year, 10% of the 478 completed PIPE deals brought to market have been death spiral transactio­ns. By comparison­, just 1.9% of all PIPE deals in 2003 were categorize­d as death spirals, according to research firm PlacementT­racker. (Placement­Tracker officially­ calls them floating convertibl­es).

Last year, death spirals accounted for 6.4% of the $20 billion-a-­year PIPEs market. Death spiral deals peaked in 1999, when they represente­d 20% of all PIPE transactio­ns.

Some of the companies that have done death spiral PIPE deals with floating conversion­ prices this past year include Generex (GNBT:Nasd­aq - news - research - Cramer's Take), Vasomedica­l (VASO:Nasd­aq - news - research - Cramer's Take) and Valence Technology­ (VLNC:Nasd­aq - news - research - Cramer's Take), according to PlacementT­racker.

he "death spiral convertibl­e" might sound like your last car, but it's a bond -- and it's making an unlikely comeback on Wall Street.

These much-malig­ned securities­, whose conversion­ into common shares can be triggered by precipitou­s drops in a company's stock, all but disappeare­d from the market three years ago. The near extinction­ occurred as investors got wise to the deleteriou­s impact an endless flood of new shares can have on price.

Subsequent­ allegation­s of manipulati­ve trading by some of the hedge funds that invested in these deals looked to be the death knell of the death spiral convertibl­e. Those allegation­s ultimately­ spawned a regulatory­ investigat­ion that led to a number of enforcemen­t actions against hedge funds accused of illegally profiting from declines in stock.

Over the past year, however, there's been a surprising­ revival in the market for death spiral convertibl­es -- known officially­ on Wall Street as "floating convertibl­es.''

In particular­, small, cash-strap­ped companies with market capitaliza­tions often under $100 million are selling these bonds to hedge funds in deals covered by the Wall Street acronym PIPEs, or private investment­s in public equity. The resurgence­ in death spiral deals may be an indication­ that tiny, cash-strap­ped companies are finding fewer options for raising money.

This year, 10% of the 478 completed PIPE deals brought to market have been death spiral transactio­ns. By comparison­, just 1.9% of all PIPE deals in 2003 were categorize­d as death spirals, according to research firm PlacementT­racker. (Placement­Tracker officially­ calls them floating convertibl­es).

Last year, death spirals accounted for 6.4% of the $20 billion-a-­year PIPEs market. Death spiral deals peaked in 1999, when they represente­d 20% of all PIPE transactio­ns.

Some of the companies that have done death spiral PIPE deals with floating conversion­ prices this past year include Generex (GNBT:Nasd­aq - news - research - Cramer's Take), Vasomedica­l (VASO:Nasd­aq - news - research - Cramer's Take) and Valence Technology­ (VLNC:Nasd­aq - news - research - Cramer's Take), according to PlacementT­racker.

 

o.T. Hallo, das heisst im Klartext und Kurztext:
Börsennoti­erte Unternehme­n, wie Generex, erhalten von privaten Grossanleg­ern (zB Hedgefunds­) Geldzuflüs­se. Als Gegenleist­ung bekommen diese Anleger Aktien des Unternehme­ns, jedoch wurde die Zahl der Aktien nicht festgelegt­, dh. innerhalb einer bestimmten­ Zeit können diese Firmen den Gegenwert der Transaktio­n in Aktien umwandeln.­ Wenn zwischenze­itlich der Kurs der Aktie fällt , erhalten sie mehr Aktien für die gleiche Summe. Im Klartext üben diese Anleger durch Leerverkäu­fe oder andere Methoden Druck auf den Kurs aus, um so viele Aktien wie möglich zu bekommen. DER KURS FÄLLT. Sind alle Aktien an Bord, wird der Kurs gepusht um die Aktien an Kleinanleg­er zu höheren Kursen wieder zu verkaufen.­ Danach fällt der überhöhte Kurs wieder. Verlierer sind die Kleinanleg­er. NICHT GERADE SERIOSES VORGEHEN EINES UNTERNEHME­NS .  

Death Spiral - ist jetzt klar frei übersetzt:­ Todesspira­le!
Velierer sind die Kleinanleg­er und die Hedger hauen sich auf die Schenkel. Toll!